TY - JOUR
AU1 - Kitazawa, Shoko
AU2 - Chiyoda, Tatsuyuki
AU3 - Nakamura, Kohei
AU4 - Sakai, Kensuke
AU5 - Yoshihama, Tomoko
AU6 - Nishio, Hiroshi
AU7 - Kobayashi, Yusuke
AU8 - Iwata, Takashi
AU9 - Banno, Kouji
AU1 - Yamagami, Wataru
AU1 - Nishihara, Hiroshi
AU1 - Aoki, Daisuke
AB - BackgroundJapan’s health insurance covers multigene panel testing. This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology.MethodsWe analyzed the characteristics of patients with gynecologic cancer who underwent gene panel testing using FoundationOne® CDx or OncoGuide™ NCC Oncopanel between November 2019 and October 2022.ResultsOut of 102 patients analyzed, 32, 18, 43, 8, and 1 had cervical, endometrial, ovarian cancers, sarcoma, and vaginal cancer, respectively. Druggable gene alteration was found in 70 patients (68.6%; 21 with cervical cancer, 15 with endometrial cancer, 28 with ovarian cancer, 5 with sarcoma, and 1 with other). The most common druggable gene alteration was PIK3CA mutation (n = 21), followed by PTEN mutation (n = 12) and high tumor mutation burden (TMB-H) (n = 11). TMB-H was detected in 5 patients with cervical cancer, 5 with endometrial cancer, and 1 with endometrial stromal sarcoma. Eleven patients (10.8%) received molecularly targeted therapy according to their gene aberrations. Gene panel testing was mostly performed when the second-line treatment was ineffective. Of all 102 patients, 60 did not have recommended treatment, and 15 died or had worsened conditions before obtaining the test results.ConclusionThrough multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients’ prognosis and performance status should be considered before performing the test.
TI - Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer
JF - International Journal of Clinical Oncology
DO - 10.1007/s10147-023-02398-8
DA - 2023-11-01
UR - https://www.deepdyve.com/lp/springer-journals/clinical-availability-and-characteristics-of-multigene-panel-testing-ubAZKZklP2
SP - 1554
EP - 1562
VL - 28
IS - 11
DP - DeepDyve
ER -